stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Omeros Corporation

United States · NASDAQ: OMER · Market cap: · P/E: · P/S:

Omeros is a biopharmaceutical company that develops drugs for immune-related diseases, cancers, and compulsive disorders.

Omeros is a small drug developer that tries to turn biology that most companies ignore into medicines. Its most important product is Omidria, a liquid added to the fluid surgeons use during cataract surgery. It keeps the pupil from shrinking and reduces pain and inflammation after the operation, which makes the surgery easier for the doctor and more comfortable for the patient. Hospitals and surgery centers pay for it, and it has been the company's steady commercial business.

Omeros Corporation (OMER) YARTEMLEA: line art illustration of a single YARTEMLEA vial and carton, distinctive brand markings
YARTEMLEA
YARTEMLEA is Omeros's main moneymaker, treating a serious stem cell transplant complication.

The bigger bet is on the immune system's "alternative pathway," a back door way the body's complement system can attack its own tissues. Omeros built a drug, narsoplimab, to block a key switch in that pathway. Its first target was a rare and often fatal blood vessel disease that can strike after stem cell transplants. That effort hit a wall: U.S. regulators declined to approve the drug in 2021 and again in 2024, asking for more evidence that it works. The company has kept the program alive and is testing the same drug in other diseases, so a lot rides on whether those trials succeed. Omeros also has an earlier-stage pipeline, including a drug aimed at addictive and compulsive behaviors, which fits its stated focus on compulsive disorders. That work is years from market, and drug development is a brutal, expensive gamble: most candidates fail, and each trial costs a fortune. A small company like this lives or dies on trial results and on raising enough cash to keep going, which is why the narsoplimab setbacks matter so much.


Financially, Omeros is a commercial-stage company with a small revenue base from Omidria and heavy spending on research. It is not yet consistently profitable, and its future depends on getting a pipeline drug approved. Based in Seattle, it is a good example of a biotech where one regulatory decision can swing the whole story.

Saved answer · last researched 16 Nov 2026